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Abstract Genetic linkage and association methods have
long been the most important tools for gene identification in
humans. These approaches can either be hypothesis-based
(i.e., candidate-gene studies) or hypothesis-free (i.e.,
genome-wide studies). The first part of this review offers
an overview of the latest successes in gene finding for
blood pressure (BP) and essential hypertension using these
DNA sequence–based discovery techniques. We further
emphasize the importance of post–genome-wide association
study (post-GWAS) analysis, which aims to prioritize
genetic variants for functional follow-up. Whole-genome
next-generation sequencing will eventually be necessary to
provide a more comprehensive picture of all DNA variants
affecting BP and hypertension. The second part of this
review discusses promising novel approaches that move
beyond the DNA sequence and aim to discover BP genes
that are differentially regulated by epigenetic mechanisms,
includingmicroRNAs,histonemodification,andmethylation.
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Introduction
Genetic linkage and association methods have long provided
the mainstay of gene-finding efforts in humans, which can
either be hypothesis-based (i.e., candidate gene studies) or
hypothesis-free(i.e.,genome-widestudies)(Table1). Linkage
methods investigate the co-segregation of traits or diseases
with genetic markers within family members (e.g., pedigrees
or siblings), which proved to be very successful for
monogenic (or Mendelian) diseases. For complex traits and
diseases such as blood pressure (BP) and essential hyperten-
sion, positional cloning (i.e., fine mapping of linkage peaks
often harboring a large number of genes) proved unsuccess-
ful, however, because the inheritance of these traits and
diseases does not fit a simple Mendelian pattern. In a
landmark paper, Risch and Merikangas [1]s h o w e dt h a t
linkage analysis has minimal power to detect genes for
complex traits and diseases. As a consequence, gene-finding
efforts have increasingly come to rely on association
approaches [2]. Association studies test whether a particular
genetic marker and a trait co-occur more often than expected.
In contrast to linkage analysis, these studies typically are
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tion (but see the review by Ott et al. [3] for the exception to
this rule).
Association studies have been greatly facilitated by the
sequencing of the human genome, in combination with
major efforts to discover single nucleotide polymorphisms
(SNPs), such as the International HapMap Project [4]. The
increased availability of SNPs resulted in the development
of two new association approaches: (1) indirect (or gene-
wide) candidate gene studies considering all common
variants within the gene jointly, and (2) the genome-wide
association study (GWAS). Rapid improvements in SNP
genotyping technology and reductions in cost have now
made it feasible to conduct GWASs, which have led to an
explosion in the number of newly identified genes for
complex traits and diseases [5].
Although developed only recently, large-scale SNP geno-
typing in the context of GWASs will soon be superseded by
next-generation high-throughput DNA sequencing. This
technology allows for rapid and efficient sequencing of
candidate genes; it is increasingly being applied to whole
exomes and even whole genomes [6].
This review first gives an overview of the latest successes
in gene finding for BP and hypertension using discovery
techniques based on the DNA sequence (Table 1). Results of
recent GWASs are not discussed in depth, as they have been
reviewed elsewhere [7–9]; instead, we focus on post-GWAS
analysis, which aims to prioritize genetic variants for
functional follow-up. The second part of this review
discusses novel strategies aiming to identify BP genes for
which differential regulation of their expression is not coded
in their DNA sequence—that is, gene discovery techniques
focusing on epigenetic regulation, including microRNAs
(miRNAs), histone modification, and methylation.
DNA Sequence–Based Strategies
Hypothesis-Based (Candidate Gene) Studies
From 1996 until 2004, over 100 candidate gene linkage
studies for BP and hypertension were published, targeting
at least 26 candidate genes [10]. Results were largely
inconclusive, owing to lack of power and low mapping
resolution.
Until recently, candidate gene association studies for BP
and hypertension, especially the so-called direct association
studies testing only one or two potentially functional SNPs,
also yielded few consistently replicated candidates [11].
However, some headway has been made in the past few
years in studies using larger sample sizes combined with
higher-throughput strategies for genotyping common SNPs
and rigorous control of multiple tests.
Newton-Cheh et al. [12•] genotyped a set of 13 SNPs in
14,743 individuals, capturing the majority of common
variation at the NPPA-NPPB locus harboring the genes that
code for atrial and B-type natriuretic peptides. Strong
associations were found for a number of SNPs with both
atrial and B-type natriuretic peptides. In 29,717 individuals,
the alleles of rs5068 and rs198358 that showed association
Table 1 DNA sequence–based strategies of gene identification applied to blood pressure (BP) and hypertension (HTN)
Strategy Genetic markers/variants Mapping resolution
a Gene identification for BP/HTN?
Hypothesis-based
Candidate gene linkage Microsatellites Low Inconclusive
Candidate gene association
b
Direct Functional SNPs Moderate Few replicated
Indirect/gene-wide Set of tagging SNPs High Some recent successes
Sequenced All variants Very high Some recent successes
Hypothesis-free
Genome-wide linkage Microsatellites Low Monogenic HTN
Genome-wide association
SNP array SNPs High BP/HTN in general population
Exome sequenced Coding variants Very high Promising
Whole genome sequenced All variants Very high Promising
aThe size and accuracy of the mapped genomic region varies as a function of the gene identification method applied. For example, linkage peaks
demarcate only broad genomic regions, requiring major fine mapping efforts to identify the underlying causal variants
bDirect candidate-gene association studies typically target a limited number of potentially functional SNPs, whereas indirect (or gene-wide)
association studies aim to capture all common variation within the gene using a set of tagging SNPs. Candidate-gene sequencing is often applied
to detect and investigate effects of previously unknown rare variants
SNP single nucleotide polymorphism
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were also found to be associated with lower systolic BP
(SBP) (0.9–1.5 mm Hg) and diastolic BP (DBP) (0.3–
0.8 mm Hg), as well as reduced odds of hypertension (OR
of 0.85 for rs5068 and 0.90 for rs198358).
A number of recent studies employed innovative
approaches to investigate association for large numbers of
candidate genes. Sõber et al. [13] used a genome-wide
genotyping array to test association of common variants
with BP and hypertension in 160 candidate genes. The
discovery sample consisted of 1,017 individuals, with
follow-up of the most significant SNPs in additional
replication cohorts. However, none of the signals survived
correction for multiple testing. Tomaszewski et al. [14] used
a custom-made gene-centric array with over 30,000
common and rare SNPs to genotype 2,020 European
individuals from 520 nuclear families with measures of
24-hour ambulatory BP available. A total of 105 candidate
genes for BP, with good genetic coverage of common
variants, were present on the array. Nevertheless, little
evidence was found for involvement of these most
frequently investigated candidate genes for BP, such as
those for the sympathetic nervous system and the renin-
angiotensin system. Interestingly, these results are in line with
those from recent GWASs [15••, 16••] in which only 2 of the
13 gene loci discovered could have been regarded as
candidate gene loci for BP (MTHFR and CYP17A1)[ 7].
However, a final successful study employing a similar
strategy indicates that expected effect sizes of common
candidate SNPs are small, making large sample sizes a
crucial requirement for the detection of their effects. Johnson
et al. [17•] investigated 30 gene regions encoding known
antihypertensive drug targets in meta-GWAS data from
29,136 individuals of the CHARGE consortium. Nominal
evidenceofassociationofADRB1, ADRB2, AGT, CACNA1A,
CACNA1C,a n dSLC12A3 polymorphisms with one or more
BP traits was observed. Replication of the top SNPs in the
GlobalBPgen Consortium (n=34,433) and the Women’s
Genome Health Study (n=23,019) resulted in genome-wide
significant results (P<5×10
-8) for rs1801253 in ADRB1
(Arg389Gly), with the Gly allele associated with a lower
mean SBP (0.57 mm Hg) and DBP (0.36 mm Hg) and with a
SNP in AGT (rs2004776) showing per allele effect sizes of
0.42 mm Hg for SBP and 0.32 mm Hg for DBP.
In addition to common variants, BP and hypertension
may be influenced by rare variants (i.e., allele frequencies<
5%) with potentially larger effect sizes. For example,
Tomaszewski et al. [14] found a significant overrepresen-
tation of rare variants amongst polymorphisms showing at
least nominal association with mean 24-hour BP. These
results did not depend on the threshold of rare variant
definition (minor allele frequency [MAF]<5% or MAF<
2%), significance level (P<0.05 or P<0.01), or the
phenotype(24-hourSBPorDBP).Resequencingofcandidate
genes offers an opportunity to detect such rare variants and
investigate their association with BP and hypertension. Rao et
al. [18] resequenced a locus critical for catecholamine
storage, chromogranin A (CHGA), and discovered a low-
frequency (3%) functional variant, Gly364Ser, which had a
strong effect on autonomic activity as well as DBP. The latter
effect was replicated in an independent sample. Similarly, Ji
et al. [19•] resequenced three renal salt-handling genes
(SLC12A3, SLC12A1,a n dKCNJ1) known to be involved
in Mendelian syndromes of salt wasting and low BP, in
individuals with the most extreme BPs in the population.
They discovered a series of rare, nonsynonymous, loss-of-
function variants associated with lower BP, clearly showing
that rare variants can produce clinically significant BP
reduction in the general population.
Hypothesis-Free (Genome-Wide) Studies
Genome-wide linkage studies have been proven successful
in identifying genes underlying monogenic forms of
hypertension and hypotension [20, 21]. Eighteen such
genes have been uncovered so far, with mutations all
directly affecting renal tubular electrolyte transport, con-
firming the key role of the kidney in BP control.
Interestingly, there are still some forms of Mendelian
hypertension for which the culprit genes remain to be
identified [22].
Finding genes for BP and hypertension through GWAS
turned out to be even more difficult than for most other
complex traits and diseases [7–9]. It was not until a large
number of studies joined forces into the GlobalBPGen and
CHARGE consortia that 13 novel BP loci were identified
[15••, 16••]. A number of subsequent GWASs have
successfully built upon these landmark studies and identi-
fied additional loci. After meta-analysis combining the
Women’s Genome Health Study with prior study results of
CHARGE, one suggestive SNP (CASZ1, also replicated in
a Japanese study [23]) and one gene expression–associated
SNP (BLK-GATA4 region) now reached genome-wide
significance [24]. The first successful GWAS for hyperten-
sion used an extreme case-control design in a discovery
sample of 1,621 hypertension cases and 1,699 hyper-
controls, representing the top 2% and bottom 20% of the
BP distribution in Sweden [25•]. Combined with follow-up
validation analyses in 19,845 cases and 16,541 controls, a
locus near the Uromodulin (UMOD) gene was identified.
UMOD is exclusively expressed in the kidney, suggesting
that the discovered variant may have an effect on sodium
homeostasis.
Extension of the GWAS approach to other ethnic groups
once more emphasizes that large sample sizes, often
achieved through meta-GWAS consortia, are essential. For
444 Curr Hypertens Rep (2011) 13:442–451example, two initial GWASs in African Americans did not
identify any genome-wide significant signals after the
replication stages [26, 27]. Admixture mapping and
subsequent follow-up association analysis may be a more
powerful alternative in such admixed populations, as shown
by Zhu et al. [28•]. They identified a novel variant
(rs7726475) on chromosome 5 between the SUB1 and
NPR3 genes, associated with both SBP and DBP. Kato et
al. [29••] recently published the first large-scale GWAS
meta-analysis for SBP and DBP in east Asians, with
discovery in 19,608 subjects from eight cohorts and further
replication in over 30,000 subjects. They confirmed seven
loci previously identified in populations of European
descent, but, much more importantly, also identified six novel
loci: ST7L-CAPZA1, FIGN-GRB14, ENPEP, NPR3, a newly
discovered variant near TBX3, and one near ALDH2. The last
locus is likely related to a nonsynonymous SNP (rs167) in
ALDH2 that is specific to east Asians. Interestingly, its strong
association with both SBP and DBP was largely mediated by
alcohol intake.
Post-GWAS Analysis
An important limitation of GWASs is that genome-wide
significant SNPs often merely tag but do not provide direct
information on the causal variants. To translate those
signals to biological function, follow-up studies are
necessary. Recently, the term post-GWAS analysis was
coined to refer to this process. The first step of post-GWAS
analysis includes a wide variety of mostly bioinformatics-
based (in silico) approaches, aiding prioritization of genes
and variants within identified loci for subsequent functional
(in vitro and in vivo) follow-up studies (Fig. 1)[ 30••]. First
a window surrounding the top SNP is defined, which is
likely to harbor the causal variant or variants. This window
is often based on the linkage disequilibrium (LD) structure
in the region, because the top SNP is assumed to pick up
the association signal through its LD with causal variants.
Alternatively, a pragmatically chosen fixed distance can be
used, such as 1 Mb on either side of the sentinel SNP, as
LD is unlikely to extend beyond this distance [31]. By
cross-comparison of the LD structure between populations
(e.g., using data from the HapMap project [4]), the region
of interest can be further narrowed.
A first glance at all variations of interest is offered by
publicly available sequence databases such as those of the
1000 Genomes Project, which comprises whole-genome
sequencing data for a large number of individuals repre-
sentative of African, Asian, and European populations
[32•]. It aims to produce a catalogue of human variation
with frequencies as low as 0.5% to 0.1% and has already
identified more than 20 million variants. This resource
greatly facilitates investigation of associated regions for
potential causal variants without the need for de novo
sequencing. However, if resequencing is deemed necessary,
next-generation sequencing is the method of choice. It has
significant advantages over traditional methods such as
Sanger sequencing or dedicated microarrays in terms of
throughput, costs, and coverage of variation [6]. It further
allows for detection of copy number variants (CNVs) [33]
and variants with lower frequencies, thereby improving the
chances of detecting a fuller range of potentially causal
polymorphisms.
Once variation within the target region is captured, the
genomic properties of the variants can be evaluated using
genome browsers such as the one from the University of
California Santa Cruz (UCSC) [34] or SNP annotation tools
such as WGAViewer [35]. SNPs identified by GWASs
often do not map within genes, complicating the interpre-
tation of the findings [36]. To narrow the list of plausible
causal variants, bioinformatic approaches are often used
that aim to prioritize SNPs based on their potential
functionality. These tools apply evaluation criteria such as
genomic location, impactongeneexpression, likely impactof
amino acid substitution on protein function, or previously
observed association with other phenotypes. Examples of
widely used software allowing such prioritization are Poly-
Phen [37], SIFT [38], and PupaSuite [39].
Additional information on the functionality of the
variants can be derived from integration of GWAS data
with “omics” data from transcripts, proteins, and metabo-
Fig. 1 This diagram illustrates how post-GWAS analysis aids the
translation of significant GWAS signals into disease mechanisms
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traits underlying variation in the phenotypic outcome
variables. For example, Annilo et al. [40] demonstrated
functional interaction at the RNA level between NPPA and
its natural antisense transcript derived from the opposite
strand. This might constitute an important post-
transcriptional mechanism modulating expression of the
NPPA gene, which falls within the MTHFR/NPPA/NPPB
locus identified in recent GWASs [16••]. Identified risk
variants may affect the causal genes not only at the RNA
level (expression quantitative trait loci or eQTLs), but also
at the level of the protein (pQTLs) or metabolites (mQTLs).
Through integration of GWAS data with these multiple
“omics” levels and epigenetic data, this systems genetics
approach may provide insight into the causal networks
underlying disease etiology [41].
GWAS loci often consist of more than one gene.
Prioritization of the most likely causal genes within these
loci can be aided by tools that attempt to reconstruct
regulatory networks and metabolic pathways in which these
genes operate. Depending on the approach, these tools may
rely on protein-protein interaction and/or mRNA co-
expression databases, as in STRING [42], or on established
metabolic networks such as KEGG [43]. Evidence of
interaction might also be based on computational predic-
tion, literature mining, or wet-lab experiments.
Theabove-mentionedmethodsthataidintranslatingGWAS
findings into actual disease mechanisms depend heavily on
computational approaches. Validation of the causality of
identified variants and genes requires functional follow-up
studies employing both in vitro and in vivo experiments.
Sources of Missing Heritability
Despite recent successes, the collective effect of BP loci
identified through GWASs explains only a small fraction
(< 1%) of BP heritability, which is estimated to range
between 30% and 60% on the basis offamily and twin studies
[44, 45]. Expansion of GWAS sample size in the Interna-
tional Consortium on BP (ICBP)-GWAS, a merger of
GlobalBPGen and CHARGE, is likely to uncover additional
common BP variants [7], but they will have even smaller
effect sizes, and a substantial increase in explained heritability
of all loci combined is not expected. Finding suitable answers
to the missing heritability enigma is currently the most
important challenge in BP and hypertension genetics. Besides
additional common variants of small effect, rare variants and
structural variations such as copy number variants (CNVs)
(>1 kb) or smaller (<1 kb) insertion-deletion polymorphisms
(indels) are likely sources of missing heritability. Haplotype
analysis can be used to extract rare variant effects from the
common variants interrogated by the GWAS arrays. Applica-
tion of this approach to the Wellcome Trust Case Control
Consortium (WTCCC) GWAS data identified rare variants at
the ZFAT1 gene affecting hypertension [46]. The WTCCC
study also investigated effects of common CNVs on eight
complex diseases, including hypertension, but did not detect
any associations for hypertension. It is thus unlikely that
common CNVs that can be typed on existing platforms
contribute greatly to the missing BP and hypertension
heritability [47]. Knowledge of the involvement of indels
in complex disease is limited, as no high-throughput
detection technology is available. Indels include poly-
morphic transposable elements, inserted copies of which
could interrupt structurally or functionally important ge-
nomic regions and affect the expression of a locus. Examples
of Alus exhibiting replicated association with BP are the
classic polymorphic Alu-insertion (rs4646994: I/D) located
in intron 16 of the ACE gene [48] and a recently discovered
AluYb8 insertion in intron 10 of the WNK1 gene [49].
Next-generation high-throughput sequencing techniques
of whole exomes and genomes (Table 1) are necessary to
provide a more comprehensive picture of the variants
hidden in the DNA sequence, which may allow us to close
at least part of the heritability gap.
Beyond the DNA Sequence: Epigenetics
Not all gene regulation is coded in the DNA sequence. The
second part of this review discusses techniques that aim to
discover BP genes that are differentially regulated by
epigenetic mechanisms, including miRNAs, histone modi-
fication, and methylation.
Role of miRNAs in Blood Pressure Regulation
miRNAs are small (~22 nucleotides), regulatory, single-
stranded RNA molecules, which function by reducing the
expression of specific target genes. This method of gene
silencing was initially discovered in C. elegans, but the
mechanism has proven to be prevalent in most multicellular
animals [50]. miRNAs are endogenous in origin and are
transcribed as longer precursor RNA molecules that are
processed into mature miRNAs capable of reducing the
translation levels from the targeted mRNA and/or causing
its degradation [51]. Currently, more than a thousand
miRNAs have been identified in humans [52]. As miRNAs
target a large proportion of mammalian genes, they may
represent one of the major mechanisms of regulating gene
expression, alongside the transcription factors. miRNAs
participate in almost all cellular processes, including
proliferation, differentiation, and cell death. They modulate
developmental processes and cell cycle control and exhibit
pervasive dysregulation in cancerous states [53]. There is
substantial evidence regarding the roles of microRNAs in
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cardiovascular tissues and consequently in cardiovascular
disease; extensive reviews of this evidence are available
[54–56]. However, the evidence for miRNA involvement in
everyday metabolic processes is still limited.
Given the extent of miRNA regulation and the com-
plexity of BP-regulating networks, it is highly likely that
miRNAs also modulate BP homeostasis. Although early
work on Dahl salt-sensitive rats did not identify differences
in miRNA expression profile in the kidneys and heart
between animals on a normal diet and a high-salt diet [57],
recent studies in genetically similar SS-13BN rats have
revealed increased expression of miR-29b in response to
high salt intake [58]. Tissue or cell-type specific Dicer-
knockout mice have demonstrated the importance of
miRNAs in the development and maintenance of BP-
regulating cells. So far, such models have been created for
vascular smooth muscle cells (VSMCs) [59•], juxtaglomer-
ular cells [60], and podocytes [61–63]. The loss of miRNAs
in juxtaglomerular cells and VSMCs causes significant
reductions of BP. In case of juxtaglomerular cells, this
difference can be attributed to reduced renin production
[60], whereas in VSMCs the reduced BP is due to
decreased vascular contractility, which can be attributed to
a large extent (but not entirely) to the lack of miR-145 [59•,
64]. In addition to regulating BP by maintaining vascular
contractility, several components of the renin-angiotensin-
aldosterone system have been found to be under miRNA
control. One experimentally confirmed example is the
mineralocorticoid receptor gene NR3C2, downregulated by
miRNAs miR-135a and miR-124 [65]. Interestingly, the
miRNA-155 binding site in the 3′ untranslated region (UTR)
of the angiotensin II receptor 1 (AGTR1) gene carries a
polymorphism that leads to differential interaction between
mRNA and miRNA and affects BP levels in the general
population [66, 67••]. Bioinformatic analyses of the genes in
the renin-angiotensin-aldosterone system indicate that several
additional genes are potentially regulated by miRNAs [65,
68], and the predicted miRNA binding sites contain poly-
morphisms that may contribute to the interindividual BP
variation [68]. For example, a potential polymorphic miRNA
binding site has been reported in the 3′UTR of the
neuropeptide Y1 receptor gene [69].
Thus, miRNAs are critically involved in regulating BP,
both by maintaining cellular identities in tissues responsible
for BP regulation and by maintaining peripheral vascular
tension and central regulation of blood volume by modu-
lating the renin-angiotensin-aldosterone system. Improved
understanding of the dynamics of the miRNA profile, its
effect on the expression of BP regulating genes, and
interplay with genetic variation in the miRNA binding sites
may uncover part of the missing BP heritability.
Role of Histone Modification in Blood Pressure Regulation
Histone proteins (H1–4) are major proteins in the chroma-
tin. The four core histones, H2A, H2B, H3, and H4, may
undergo a range of posttranslational modifications, includ-
ing acetylation, methylation, O-GlcNac modification, phos-
phorylation, SUMOylation, adenosine diphosphate (ADP)
ribosylation, and ubiquitination [70]. Histone modifications
are indicators of active or repressed chromatin, and the
“histone code” hypothesis proposes that combinations of
specific histone modifications define chromatin regulation
and gene transcription [71, 72]. For example, methylation
of histone H3 on lysines 4 and 36 (H3K4 and H3K36) is
generally associated with an open euchromatin structure
and transcriptional activation, whereas methylation of
histone H3 on lysines 9 and 27 (H3K9 and H3K27) is
generally associated with a closed heterochromatin struc-
ture and gene silencing.
Evidence on the role of histone modification in BP
regulation derives from animal and in vitro studies on
genes causally linked with hypertension. One example is
the epithelial sodium channel (ENaC) gene. ENaC plays a
major role in sodium reabsorption and hence in the
regulation of BP, as evidenced by the findings of
mutations in ENaC genes associated with the genetic
hypertensive and hypotensive diseases, Liddle’s syndrome
[73] and pseudohypoaldosteronism type 1 [74]. The
studies by Zhang et al. [75]i nm o u s ea n dc e l ll i n e s
explored whether histone modification can control epithe-
lial sodium channel-α subunit (ENaCα) gene expression
in the collecting duct and discovered that a nuclear
repressor complex can regulate histone H3 Lys-79 meth-
ylation of chromatin associated with the ENaCα promoter
and suppress its transcriptional activity. Aldosterone can
disrupt this nuclear complex and result in histone H3 Lys-
79 hypomethylation at specific subregions and de-
repression of the ENaCα promoter. Another example is
WNK lysine–deficient protein kinase 4 (WNK4). The
WNK family of serine-threonine kinases has a key role in
renal tubular sodium reabsorption. Individuals with pseu-
dohypoaldosteronism II carrying loss-of-function muta-
tions in the WNK4 gene show salt-sensitive hypertension
[76]. A recent study by Mu et al. [77•]i nm i c eo nah i g h -
salt diet showed that histone modification plays an
important role in decreasing transcription of the WNK4
gene induced by β2-adrenergic receptor stimulation.
Specifically, isoproterenol-induced transcriptional sup-
pression of the WNK4 gene is mediated by histone
acetylation in the promoter region of the WNK4 gene via
inhibition of histone deacetylase-8 activity. These results
suggest that histone modification mechanisms affecting
these genes are causally linked to hypertension.
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DNA methylation, the best known epigenetic modification,
involves the addition of a methyl group to cytosines within
CpG pairs. This process is intrinsically linked to the
regulation of gene expression. The methylation of these
CpG sites, overrepresented in CpG islands in the promoter
regions of many genes, disrupts the binding of transcription
factors and attracts methyl-binding proteins that are
associated with gene silencing and chromatin compaction
[78, 79]. Aberrant de novo methylation of CpG islands is a
hallmark of human cancers and is found early during
carcinogenesis [80]. Besides cancer, methylation changes of
genes have recently been linked to a wide range of
complex, often age-related diseases, including hypertension
[81], diabetes [82], autoimmune disorders [83], obesity
[84], heart disease [85], and mental disorders [86].
In a genome-wide methylation study in Dahl salt-
sensitive rats, more than 1,000 hypermethylated CpG sites
were identified in the kidneys of salt-sensitive rats
compared with normotensive Brown Norway rats. Further
pyrosequencing of the promoter of renin genes showed that
10 CpG sites were significantly hypermethylated in salt-
sensitive rats, consistent with the reduced renin expression
in this strain [87]. This study shows evidence that
methylation may underlie salt-sensitive hypertension. In
addition to salt intake and other postnatal environmental
factors, there is now substantial evidence that an adverse
fetal environment may program development of hyperten-
sion in later life [88–91]. Because DNA methylation takes
place in this critical time window, it has been suggested as a
good candidate mechanism that may potentially serve as the
link between early environmental influences and hyperten-
sion [92]. This has been confirmed by Bogdarina et al. [93].
They found significant undermethylation of the proximal
promoter of the angiotensin II receptor AT1b gene in the
adrenals from offspring of mothers fed a low-protein diet.
This is consistent with the increased expression of the AT1b
gene in the adrenal gland and higher BP observed in this rat
model. These data suggest that methylation modification of
genes represents a link between fetal insults and alteration
of gene expression in adult life, leading ultimately to the
development of hypertension.
Other genes investigated for epigenetic effects on
hypertension in animal studies or in vitro studies are those
genes for which exonic mutations have unambiguously
been shown to induce hypertension. One example is the
11beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2)
gene (HSD11B2). Loss-of-function mutations of this gene
lead to a form of salt-sensitive monogenic hypertension
[94]. Methylation modulation of this gene has recently been
demonstrated in both a rodent model and cultured human
cell lines [95]. CpG islands covering the promoter and first
exon of HSD11B2 were found to be densely methylated in
tissues and celllines withlow expressionbut not inthose with
high expression of 11β-HSD2. Demethylation enhanced the
transcriptionandactivityoftheenzymeinhumancellsinvitro
and in rats in vivo. Methylation of HSD11B2 promoter-
luciferase constructs decreased transcriptional activity, and
methylation of recognition sequence of transcription factors
known to be relevant for the expression of this enzyme
diminished their binding activity [95]. A recent study [96]
also showed increased methylation of several CpG promoter
sites of HSD11B2 in kidneys from rat offspring suffering
from intrauterine growth restriction.
Data on humans are scarce. In one study, Friso et al. [97]
measured promoter methylation of the HSD11B2 gene in
peripheral-blood mononuclear cells from patients with
hypertension and 32 patients on prednisone therapy. Elevated
HSD11B2 promoter methylation was associated with
decreased HSD11B2 activity and hypertension development
in glucocorticoid-treated patients. In a recent study by
Smolarek et al. [98], significantly lower global DNA
methylation levels were observed in patients with hyperten-
sion. Further evidence comes from studies on DNA methyl-
ation profiling of preeclampsia, a disease characterized by high
BP in pregnancy. Both candidate-gene and genome-wide
approaches have confirmed that epigenetic features are
implicated in the pathogenesis of preeclampsia. For example,
in a recent genome-wide methylation analysis [99], differen-
tially methylated CpG sites were identified in a genome scan
of cases with early-onset preeclampsia versus controls. Four
loci could be further replicated in a larger sample, and one
locus was shown to affect gene expression.
Based on the convincing evidence from animal studies and
the promising evidence from small-scale human studies and
from hypertension-related diseases, large-scale epigenome-
wide human studies are needed not only to confirm the role of
methylation mechanisms in hypertension but also to identify
the specific CpG sites responsible for the global methylation
differences in hypertension.
Conclusions
GWAS has proved to be a breakthrough technology for
identification of genetic determinants of BP and hyperten-
sion, although so far it has allowed us only to scratch the
surface, with most of the heritability still missing [9].
Moreover, additional work is needed to translate genome-
wide significant signals to biological function, with post-
GWAS analysis constituting a crucial first step. Finding
suitable answers to the missing heritability problem is
currently the most important challenge in BP and hyper-
448 Curr Hypertens Rep (2011) 13:442–451tension genetics. Whole-genome sequencing may eventually
be necessary to provide a more comprehensive picture of all
DNAvariants affecting BP and hypertension. Recently, some
promising approaches have emerged that move beyond the
DNA sequence and focus on identification of BP genes
regulatedbyepigeneticmechanismssuchasmiRNAs,histone
modification, and methylation. Such studies are urgently
needed, not only to identify epigenetic variants that may
contribute to the missing heritability, but perhaps even more
importantly, to identify those that mediate differential gene
expression resulting from environmental influences.
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